Treating Chronic Hepatitis C With tMavyre

By James Myhre and Dennis Sifris, MD

Mavyret (glecapravir, pibrentasvir) is a fixed dose combination drug used in the treatment of chronic hepatitis C (HCV) infection. The drugs used in Mavyret work by blocking two individual proteins that the virus needs to replicate.

Mavyret was approved on August 3, 2017 by the U.S. Food and Drug Administration for use in adults 18 and over. Research suggests that the drug can achieve cure rates of between 92 percent and 100 percent depending HCV subtype, a figure that is more or less in line with other direct-acting antivirals (DAAs) currently used in hepatitis C treatment.

learn much more>>>https://www.verywellhealth.com/treating-hepatitis-c-with-mavyret-glecapravir-pibrentasvir-4159731?utm_campaign=hepc_symptoms&utm_source=Goo&utm_medium=con&utm_content=4061